Martin Reck and Hans Hoffmann discuss the optimal clinical trial endpoints and patient selection for neoadjuvant and adjuvant immunotherapy for resectable non-small-cell lung cancer (14:58).
Martin Reck and Hans Hoffmann discuss the optimal clinical trial endpoints and patient selection for neoadjuvant and adjuvant immunotherapy for resectable non-small-cell lung cancer (14:58).
Don’t fall behind!
Get the latest headlines – in your specialties of choice – delivered straight to your inbox.medwireNews Deputy Bureau Chief
© 2023 Springer Healthcare Limited.
Part of the Springer Nature Group.